Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

November 18, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

July 13, 2026July 13, 2026

Why Do We Age? The Biology Of Ageing Explained

1
October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

2
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

3
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

4
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

5
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • Witnessing rays of hope as the first Ebola treatment wins approval by FDA

TERI Trainee Research Associate Job For Food Technology | Apply Online

New Acyl CoA synthetase 4 inhibitor reduces breast and prostate tumour growth

Witnessing rays of hope as the first Ebola treatment wins approval by FDA
  • BiotechToday
  • World

Witnessing rays of hope as the first Ebola treatment wins approval by FDA

bioxone October 19, 2020October 19, 2020

Surupa Chakraborty, Amity University Kolkata

The U.S. Food and Drug Administration recently approved Inmazeb, a potent treatment involving a cocktail of three lab-made monoclonal antibodies (atoltivimab, maftivimab, and odesivimab-ebgn) to fight against Ebola, one of the world’s deadliest diseases known so far. Inmazeb targets the glycoprotein, which latches onto the cell surface receptors and fuses with the host cell membranes, allowing the virus to enter into the cell. The combination of three mAbs can bind with the glycoprotein and block the attachment and entry of the virus into the host cell.

Zaire ebolavirus is one of the five viruses that causes an often fatal hemorrhagic fever known as Ebola virus disease (EVD), associated with a mortality rate as high as 90%. Upon infection, the virus attacks the immune system, rapidly multiplies and begins damaging the blood vessels causing the trademark hemorrhagic rash. This is followed by widespread organ failure and death within 16 days. Since 1976, there have been a dozen major Ebola outbreaks with the recent one, being the deadliest. Several EVD therapeutics, including the Inmazeb, were evaluated in randomized clinical trials (the PALM trial) as options for preventing and treating EVD during the outbreak in 2018-2019. The trial data analysis revealed that 33.8% of the patients who were intravenously administered with Inmazeb, resulted in an extensive time of death (28 days) compared to 51% of the patients who received the investigational control.

However, common symptoms of Ebola virus infection like fever, chills, hypersensitivity reaction, tachycardia, bradycardia might also be observed while receiving the Infameb mAb treatment. Patients who will receive the treatment should avoid the consecutive administration of any live vaccine due to the treatment’s potential to inhibit the live vaccine virus replication and possibly reduce the vaccine’s efficiency. Saphire, who leads a research consortium focused on studying potent antibody treatments for Ebola, hopes that the recent FDA approval would remove all regulatory obstacles, thereby allowing the doctors and medical associations to get easy access of the drug from the US and deploy them in the affected regions.

Also read: Efficient and cost-effective Bacterial mRNA sequencing causing ribosomal RNA depletion

Source: 

  • FDA Approves First Treatment for Ebola Virus. 

https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-ebola-virus

  • Why Do We Age? The Biology Of Ageing Explained
  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged and odesivimab-ebgn atoltivimab biosafety level clinical trials Ebola outbreak ebola virus vaccine Inmazeb treatment effectiveness maftivimab monoclonal antibodies viral virulence

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • World

New Acyl CoA synthetase 4 inhibitor reduces breast and prostate tumour growth

bioxone October 19, 2020

Rohit Bhattacharjee, Amity University Kolkata Acyl CoA synthetase 4 (ACSL4) is an isoenzyme of the fatty acid ligase-coenzyme A family that takes part in arachidonic acid metabolism and steroidogenesis. ACSL4 is involved in tumour aggressiveness in breast and prostate tumours through various signal transduction pathways regulation. A well-validated ACSL4 inhibitor, however, has not been reported […]

Acyl CoA

Related Post

  • BiotechToday
  • World

Pet foods are dangerous!

bioxone July 13, 2021July 12, 2021

Monika R, PSG College of Technology, Coimbatore Most people are pet lovers, especially crazy about dogs. This is because as said by George Eliot, “Animals are such a pleasant and cheerful friend as they ask no questions and pass no criticism”. So, humans have shared their lives with animals, as they’re the best companions from […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Early Decrease in Atmospheric CO2 Concentration Caused Polar Ice Formation

BioTech Today October 26, 2021October 26, 2021

Subhajit Nan, Amity University, Kolkata New research has found out that a drop in atmospheric carbon dioxide concentration caused a sudden high cooling of the temperature when dinosaurs roamed the world, resulting in the formation of polar ice caps. Purpose of the Study A thorough study of the effects of fluctuations in the levels of […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

New AI technology aids to cater to ozone problems!

bioxone June 26, 2021June 25, 2021

Avani Dave, Jai Hind College The current technology can accurately prognosticate the ozone levels in the troposphere of the earth, just 3 days in advance. This seemed sufficient until technology took a leap, birthing the latest discovery that promises an accurate forecast around 2 weeks prior. The birthplace of this system was in The University […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

Why Do We Age? The Biology Of Ageing Explained

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy